You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

ARAMINE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Aramine, and when can generic versions of Aramine launch?

Aramine is a drug marketed by Merck and is included in one NDA.

The generic ingredient in ARAMINE is metaraminol bitartrate. There is one drug master file entry for this compound. Additional details are available on the metaraminol bitartrate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Aramine

A generic version of ARAMINE was approved as metaraminol bitartrate by AZURITY on August 24th, 2021.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ARAMINE?
  • What are the global sales for ARAMINE?
  • What is Average Wholesale Price for ARAMINE?
Summary for ARAMINE
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 52
DailyMed Link:ARAMINE at DailyMed
Drug patent expirations by year for ARAMINE

US Patents and Regulatory Information for ARAMINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck ARAMINE metaraminol bitartrate INJECTABLE;INJECTION 009509-002 Dec 22, 1987 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

ARAMINE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for ARAMINE (Metaraminol Bitartrate Injection)

Market Overview

The global market for ARAMINE, also known as metaraminol bitartrate injection, is a specialized segment within the pharmaceutical industry. This drug is primarily used to prevent and treat acute hypotensive states, particularly those occurring with spinal anesthesia, and in managing shock and hemodynamic instability.

Market Size and Growth

The metaraminol bitartrate injection market was valued at approximately USD 300 million in 2023 and is projected to reach about USD 450 million by 2033, growing at a Compound Annual Growth Rate (CAGR) of 4.1% from 2024 to 2033[4].

Key Drivers of Growth

Increasing Incidence of Hypotensive Episodes

The rising incidence of hypotensive episodes and the growing need for reliable and effective vasopressor agents are significant drivers of the market. As cardiovascular and critical care conditions become more prevalent, the demand for metaraminol bitartrate injections is expected to increase[4].

Unique Mechanism of Action

Metaraminol bitartrate offers a distinct mechanism of action compared to other vasopressor drugs, making it an essential component of emergency and critical care management. Its positive inotropic effect on the heart and peripheral vasoconstrictor action are crucial in restoring and maintaining blood pressure[5].

Regulatory Approvals and Inclusion in Essential Medicine Lists

Regulatory approvals and the inclusion of metaraminol bitartrate in essential medicine lists have contributed to its widespread adoption in healthcare settings. This recognition further solidifies its position in the market[4].

Regional Analysis

North America

North America, particularly the United States, is a leading market for metaraminol bitartrate injections. The well-established healthcare infrastructure and high adoption of critical care practices in this region drive the market's growth[4].

Europe

Europe is another prominent market, with countries like Germany, the United Kingdom, and France playing important roles. The region's advanced healthcare systems and high demand for critical care medications contribute to the market's expansion[4].

Asia-Pacific

The Asia-Pacific region is expected to experience the fastest growth, fueled by the increasing prevalence of cardiovascular diseases, expanding healthcare systems, and growing awareness about the importance of effective hypotension management[4].

Latin America and Middle East & Africa

These regions present opportunities for market growth, although the availability and adoption of metaraminol bitartrate injections may be relatively lower compared to other regions. As healthcare infrastructure and awareness improve, these markets are expected to grow[4].

Competitive Landscape

The metaraminol bitartrate injection market is characterized by the presence of a few key players, including Merck & Co., Inc., Tianjin Kingyork Pharmaccuticals Co., Ltd., Beijing SL Pharmaceutical Co., Ltd., and Shanghai Harvest Pharmaceutical Co., Ltd. These companies have established a strong foothold in the production and distribution of metaraminol bitartrate injections[1].

Financial Trajectory

Revenue Projections

The global metaraminol bitartrate injection market is projected to grow from USD 300 million in 2023 to approximately USD 450 million by 2033. This growth is driven by increasing demand, advancements in emergency and critical care medicine, and the integration of technological innovations[4].

Cost and Pricing

The cost of metaraminol bitartrate injections can vary based on regional healthcare policies and reimbursement structures. In regions with well-established healthcare infrastructures, the cost is generally covered by insurance, making the drug more accessible. However, in regions with limited healthcare infrastructure, the cost can be a significant barrier to adoption[4].

Challenges and Opportunities

Challenges

Despite the growth potential, the market faces challenges such as limited healthcare infrastructure and funding in certain regions, as well as the potential for supply chain disruptions. These factors can restrain the market's expansion and affect the availability of the drug in some areas[4].

Opportunities

Emerging markets in regions like Asia-Pacific, Latin America, and the Middle East & Africa present untapped potential. The integration of technological advancements, such as more user-friendly delivery systems or innovative formulations, can further enhance the accessibility and convenience of these injections. Additionally, the development of novel formulations or combination products may lead to more comprehensive and effective metaraminol bitartrate injection solutions in the future[4].

Ongoing Research and Development

Ongoing research and development efforts to improve the formulations, delivery methods, and safety profiles of metaraminol bitartrate injections are further driving the market's growth. These advancements aim to enhance patient outcomes and make the drug more effective and safer to use[4].

Conclusion

The metaraminol bitartrate injection market, driven by the increasing prevalence of cardiovascular and critical care conditions, is poised for continued growth. The unique mechanism of action of metaraminol bitartrate, regulatory approvals, and technological innovations are key factors contributing to this growth. While challenges exist, the opportunities in emerging markets and the potential for further innovation make this market an important segment within the pharmaceutical industry.

Key Takeaways

  • The global metaraminol bitartrate injection market is projected to grow from USD 300 million in 2023 to USD 450 million by 2033.
  • The market is driven by the rising incidence of hypotensive episodes and the need for effective vasopressor agents.
  • North America and Europe are leading markets, with the Asia-Pacific region expected to experience the fastest growth.
  • Key players include Merck & Co., Inc., Tianjin Kingyork Pharmaccuticals Co., Ltd., and others.
  • Ongoing research and development are crucial for market growth.
  • Emerging markets and technological innovations present significant opportunities.

FAQs

What is ARAMINE (metaraminol bitartrate) used for?

ARAMINE (metaraminol bitartrate) is used to prevent and treat acute hypotensive states, particularly those occurring with spinal anesthesia, and in managing shock and hemodynamic instability[5].

What is the projected market size for metaraminol bitartrate injections by 2033?

The global metaraminol bitartrate injection market is projected to reach approximately USD 450 million by 2033[4].

Which regions are expected to drive the growth of the metaraminol bitartrate injection market?

North America, Europe, and the Asia-Pacific region are expected to drive the growth of the metaraminol bitartrate injection market, with the Asia-Pacific region experiencing the fastest growth[4].

What are the key challenges facing the metaraminol bitartrate injection market?

The key challenges include limited healthcare infrastructure and funding in certain regions, as well as the potential for supply chain disruptions[4].

What role do regulatory approvals play in the market growth of metaraminol bitartrate injections?

Regulatory approvals and the inclusion of metaraminol bitartrate in essential medicine lists have contributed significantly to its widespread adoption in healthcare settings, driving market growth[4].

Sources

  1. QYResearch: Global Metaraminol Bitartrate Injection Market Research Report 2023.
  2. SciELO: Evaluation of drug utilisation pattern and cost associated with non-insulin-dependent diabetes mellitus.
  3. Milliman: Commercial drug trends: 2024 release.
  4. DataHorizzonResearch: Metaraminol Bitartrate Injection Market Size, Share, Growth.
  5. RxList: Aramine (Metaraminol): Side Effects, Uses, Dosage.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.